• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Axsome Thera (NQ: AXSM )

    85.56 +0.71 (+0.83%)
    Streaming Delayed Price Updated: 1:58 PM EDT, Jul 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 179,809
    Open 86.42
    Bid (Size) 85.47 (1)
    Ask (Size) 85.64 (10)
    Prev. Close 84.85
    Today's Range 83.88 - 86.79
    52wk Range 55.02 - 98.40
    Shares Outstanding 47,190,970
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Decoding 9 Analyst Evaluations For Axsome Therapeutics
    Via Benzinga
    Bull Market and Beyond: 2 Stocks Just Waiting to Soar
    These innovative drugmakers are hard to ignore. 
    Via The Motley Fool

    Performance

    YTD
    +11.02%
    +11.02%
    1 Month
    +12.00%
    +12.00%
    3 Month
    +20.33%
    +20.33%
    6 Month
    -5.90%
    -5.90%
    1 Year
    +16.40%
    +16.40%

    More News

    Read More
    Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    The 3 Best Biotech Stocks to Buy in July 2024
    Via InvestorPlace
    3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
    Via InvestorPlace
    Should You Buy This Sinking Stock on the Dip?
    Via The Motley Fool
    15 Analysts Assess Axsome Therapeutics: What You Need To Know
    Via Benzinga
    Why Axsome Therapeutics Stock Is Sinking Today
    Via The Motley Fool
    Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics to Participate in Upcoming Investor Conferences
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Hello Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    3 Monster Stocks in the Making You Can Buy Right Now
    Via The Motley Fool
    The 3 Most Undervalued Biotech Stocks to Buy in May 2024
    Via InvestorPlace
    Prediction: These 2 Growth Stocks Could Triple By 2030
    Via The Motley Fool
    Axsome Therapeutics to Present at Upcoming Investor Conferences
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    AXSM Stock Earnings: Axsome Therapeutics Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics Recognizes May as Mental Health Awareness Month
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.